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Background: Apoptosis is thought to play an important role in the development of acute
respiratory distress syndrome (ARDS). We evaluated the bronchoalveolar lavage (BAL) fluid
from ARDS patients focusing on apoptosis.
Methods: The study enrolled 31 ARDS patients and 20 healthy controls. BAL fluid levels of
caspase-cleaved cytokeratin-18 (CK-18) and soluble mediators such as interleukin-8 (IL-8),
soluble Fas (sFas), soluble Fas ligand (sFasL), growth-related oncogene-a (GRO-a),
granulocyte colony-stimulating factor (G-CSF), and tumour necrosis factor-related
apoptosis-inducing ligand (TRAIL) were measured using enzyme-linked immunosorbent
assay (ELISA).
Results: The BAL fluid caspase-cleaved CK-18 levels in ARDS patients were higher than
those in controls, reflecting increased epithelial apoptosis, and were correlated with lung
injury scores (rs ¼ 0.49). The BAL fluid levels of all mediators were significantly higher in
ARDS patients than in controls. In ARDS patients, the BAL fluid IL-8 level was positively
correlated with the levels of sFas (rs ¼ 0.57), GRO-a (rs ¼ 0.47), and TRAIL (rs ¼ 0.45). The
BAL fluid IL-8 (rs ¼ 0.61), sFas (rs ¼ 0.57), G-CSF (rs ¼ 0.44), and TRAIL (rs ¼ 0.33) levels
were correlated with the BAL fluid neutrophil count. The G-CSF levels were significantly
higher in non-surviving than in surviving ARDS patients [median 183.4 pg/mL (interquartile
range 76.7–315.9) vs. 63.8 pg/mL (36.2–137.2); po0.05]. The sFas levels were positively
correlated with the PaO2/FiO2 ratio (rs ¼ 0.40), and the TRAIL levels were negatively
correlated with the multiple organ dysfunction scores (rs ¼ 0.37).Elsevier Ltd. All rights reserved.
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significant prognostic implications, and the sFas and TRAIL levels were correlated with
clinical severity.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Acute respiratory distress syndrome (ARDS) is characterised
by increased permeability across the pulmonary microvas-
culature and alveolar epithelium.1 Although various inflam-
matory cells and mediators participate in the pathogenesis
of ARDS,2 the exact mechanisms of the injury and its
evolution are not clearly understood.
Apoptosis is thought to play an important role as one of
the basic pathogenic mechanisms in ARDS.3 Apoptosis in
ARDS can be viewed from two perspectives. On one hand, the
apoptosis of neutrophils is inhibited so their life span and
numbers increase, perpetuating proinflammatory reac-
tions.3,4 Several soluble mediators are reported to be
involved in inhibiting neutrophil apoptosis, including inter-
leukin (IL)-2, IL-8, granulocyte colony-stimulating factor
(G-CSF), granulocyte/macrophage colony-stimulating factor
(GM-CSF), and growth-related oncogene-a (GRO-a).5–8 On
the other hand, epithelial cells, which are the main cells
injured in ARDS, suffer from enhanced apoptosis, disrupting
the alveolo-capillary barrier.4,9 The Fas/Fas ligand (FasL)
system plays a major role in the apoptosis of epithelial
cells.10,11 It was reported that Fas and FasL were over-
expressed in bronchoalveolar lavage (BAL) cells,9 and soluble
Fas ligand (sFasL) levels in the BAL fluid of patients with
ARDS were higher in non-survivors than in survivors.11 A
subsequent study that measured soluble Fas (sFas) and sFasL
in the oedema fluids of ARDS showed that sFas, but not sFasL,
levels were related to the severity of organ dysfunction.12
Tumour necrosis factor-related apoptosis-inducing ligand
(TRAIL), well-known for its pro-apoptotic effects on tumour
cells, has also been shown to play a role under nonmalignant
conditions, acting on endothelial cells and inflammatory
chemokines.13,14 However, the role of TRAIL in ARDS has not
been evaluated.
The details of how numerous mediators are involved in
apoptosis in ARDS have not been sufficiently integrated to
determine the precise interplay of positive and negative
regulators. In fact, the interplay of the above-mentioned
mediators may be extremely complicated, and difficulties
arise in determining which mediator functions in what
direction, that is, whether it is beneficial or detrimental to
the lung injury or the clinical outcome.
We measured the levels of several known apoptosis-
related and inflammatory mediators in BAL fluid from ARDS
patients, and evaluated their interrelationships and clinical
significance.Materials and methods
Study subjects
Thirty-one ARDS patients admitted to the intensive care
units of Ajou University Hospital between August 2003 andDecember 2004 and 20 healthy volunteers were enrolled in
this prospective study. The diagnosis of ARDS followed the
definition of the American European Consensus Conference
for ARDS.15 Cases with one or more of the following were
excluded: age younger than 18 years, pregnant women,
evidence of acute myocardial infarction or heart failure,
patients medicated with steroids or immunosuppressants for
more than 2 weeks within the past 3 months, or immuno-
deficiency. At the time of enrolment, the acute physiology
and chronic health evaluation (APACHE) II scores,16 sequen-
tial organ failure assessment (SOFA) scores,17 multiple organ
dysfunction scores (MODS),18 and lung injury scores19 were
calculated for the patients. The outcome measure was the
28-day mortality after the diagnosis of ARDS. The protocol
was approved by the ethics committee of Ajou University
Hospital. Informed consent was obtained from the next
of kin.Bronchoalveolar lavage protocol
BAL was performed on the 31 patients with ARDS within 48 h
of its diagnosis, and also on the 20 healthy volunteers. The
procedure was performed at the right middle lobe or
lingular division of the left upper lobe by instilling five
separate 30-mL aliquots of 0.9% NaCl at 21 1C. The BAL
aliquots were transported to the laboratory immediately for
processing. A portion of the BAL fluid from each patient was
used for the cellular analysis. The total protein concentra-
tions in the BAL fluid were measured using the Biuret
method (Sicdia TP reagent; Eiken Chemical, Tokyo, Japan).
Total cell counts were measured using a haemocytometer.
Cytocentrifuge preparations were made using a Shandon
Cytopsin-3 (Shandon, Runcorn, UK), and the differential cell
count was performed using Wright–Giemsa staining. The BAL
fluid was centrifuged, and the supernatant was collected
and stored at 80 1C until analysis.Evaluation of epithelial apoptosis in BAL fluid
To evaluate alveolar epithelial apoptosis in BAL fluid, we
measured caspase-cleaved cytokeratin-18 (CK-18) levels
using the M30-Apoptosense enzyme-linked immunosorbent
assay (ELISA) kit (PEVIVA AB, Bromma, Sweden). CK-18 is a
type I intermediate filament protein and the major
component of epithelial cells, but it is not contained in
BAL cells (bone marrow-derived cells). The M30-ELISA assay
is based on the epitope-specific M30 antibody, which only
recognises soluble CK18 fragments cleaved at Asp396 by
caspases.20 M30 antigen levels are expressed as Units per
litre. One Unit (U) corresponds to 1.24 pmol of a synthesised
peptide containing the M30 recognition motif according to
the manufacturer.
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The concentrations of IL-8, sFas, sFasL, GRO-a, and TRAIL in
the BAL fluid were measured using quantitative sandwich
ELISA kits (R&D Systems, Minneapolis, MN, USA), and the
concentration of G-CSF was measured using an ELISA kit
(BioSource International, Camarillo, CA, USA) according to
the manufacturer’s instructions.Statistical analyses
The data were analysed using SPSS for Windows (version 12;
SPSS, Chicago, IL, USA) and the results presented as the
median (interquartile range) because the data were
nonparametric. The Mann–Whitney U-test was used to
compare the two groups. Spearman’s correlation of rank
coefficient was used to analyse correlations between
parameters, and po0.05 was considered statistically sig-
nificant.Table 1 Characteristics of the study population and
profiles of BAL fluid from the patients and controls.
Parameters ARDS patients Controls
n 31 20
Sex (male/female) 16/15 6/14
Age (years) 54.5718.4 40.2711.0
APACHE II score 17.5
(11.0–23.8)
SOFA score 6.0 (4.1–8.0)
MODS 6.0 (4.8–7.2)
Lung injury score 3.2 (2.7–3.5)
BAL parameters
Protein concentration
(mg/mL)
730
(160–1860)
100
(90–110)
Total cell count
( 104/mL)
32.0 (13–51) 5.1
(1.8–8.1)
Neutrophil count
( 104/mL)
18.0
(2.96–34.86)
0.07
(0–0.12)
Neutrophil percentage
(%)
68 (15–77) 2 (0–3)
The data, except for age, are expressed as medians, with the
interquartile range in parentheses. Age is expressed as the
mean7S.D. APACHE: acute physiology and chronic health
evaluation; SOFA: sequential organ failure assessment;
MODS: multiple organ dysfunction score.
Table 2 Comparison of the mediators in BAL fluid between AR
Mediators ARDS patients
IL-8 (pg/mL) 205.8 (83.9–537.5)
sFas (pg/mL) 747.9 (178.7–1387.6)
GRO-a (pg/mL) 759.5 (373.1–1536.9)
G-CSF (pg/mL) 108.2 (45.3–190.0)
TRAIL (pg/mL) 99.1 (50.4–177.0)
The data are expressed as medians, with the interquartile range inResults
Characteristics of the study subjects
In ARDS patients, the 28-day mortality was 58% (16/31). The
PaO2/FiO2 was 109.2 (92.3–140). The causes of ARDS were
primary pneumonia (n ¼ 24) and sepsis of extrapulmonary
origin (n ¼ 7). The baseline characteristics of the patients
and controls are presented in Table 1.Significance of caspase-cleaved CK-18 levels in BAL
fluid
BAL fluid caspase-cleaved CK-18 levels were higher in ARDS
patients than in the controls [172.3 U/L (99.3–240.4) vs.
52.3 U/L (35.8–88.0); po0.01]. BAL fluid caspase-cleaved
CK-18 levels were positively correlated with the lung injury
scores (rs ¼ 0.49, po0.01) and tended to be negatively
correlated with the PaO2/FiO2 ratio (rs ¼ 0.34, p ¼ 0.06),
but were not correlated with all the measured mediators.Comparison of mediators between ARDS patients
and controls
The BAL fluid profiles are presented in Table 1. The
concentrations of IL-8, sFas, GRO-a, G-CSF, and TRAIL in
BAL fluid were all higher in the patients with ARDS than in
the controls (Table 2). The sFasL levels were also higher in
the ARDS patients than in the controls. However, its
concentrations were very low and most were outside the
reliable detection range; thus, we did not present the actual
concentrations and omitted further analysis of sFasL.Correlation between mediators and the BAL fluid
profiles
The BAL fluid IL-8 level was positively correlated with the
levels of sFas, GRO-a, and TRAIL. The sFas level was
positively correlated with TRAIL and G-CSF levels. The
TRAIL level was positively correlated with GRO-a level
(Table 3).
The BAL fluid IL-8 (rs ¼ 0.61, po0.01), sFas (rs ¼ 0.57,
po0.01), G-CSF (rs ¼ 0.44, po0.05), and TRAIL (rs ¼ 0.33,
po0.05) levels were significantly correlated with the
neutrophil count in the BAL fluid of ARDS patients.DS patients and controls.
Controls p-Value
11.9 (9.9–17.9) o0.01
52.7 (38.9–66.9) o0.01
343.8 (250.1–499.7) o0.01
2.0 (1.6–3.9) o0.01
7.1 (4.0–16.6) o0.01
parentheses.
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When the levels of mediators were compared between
survivors and non-survivors, only the G-CSF levels differed
significantly and were higher in non-survivors than in
survivors. The BAL fluid IL-8 levels were slightly higher,
and the sFas, TRAIL, and GRO-a levels were slightly lower in
non-survivors than in survivors without reaching statistical
significance (Table 4).
The BAL fluid sFas levels were positively correlated with
the PaO2/FiO2 ratio (rs ¼ 0.40, po0.05), and the TRAIL
levels were negatively correlated with the MODS
(rs ¼ –0.37, po0.05). The TRAIL levels were also negatively
correlated with APACHE II and SOFA scores, although
statistical significance was not achieved.
Discussion
Neutrophils and epithelial cells are two major objects of
apoptosis in ARDS. Delayed apoptosis of intra-alveolar
neutrophils was previously demonstrated.6 Structural al-
terations due to increased apoptosis of alveolar epithelial
cells have also been documented.21 In the present study, we
found increased alveolar epithelial apoptosis and observed
its correlation with the severity of lung injury, indirectly
through BAL fluid analysis.
Various apoptosis-related mediators measured using in
vivo and in vitro methods play roles in ARDS.4 This study
examined the up-regulation and interrelationship of apop-
tosis-related mediators in ARDS, and documented their
clinical implications.Table 3 Spearman correlation coefficients between the
mediators in BAL fluid from ARDS patients.
IL-8 s-Fas GRO-a G-CSF TRAIL
IL-8 1
s-Fas 0.57y 1
GRO-a 0.47y NS 1
G-CSF NS 0.55 NS 1
TRAIL 0.45 0.49y 0.40 NS 1
NS, not significant.
po0.05.
ypo0.01.
Table 4 Comparison of the levels of mediators between surviv
Mediators Survivors (n ¼ 15)
IL-8 (pg/mL) 161.8 (83.9–454.5)
sFas (pg/mL) 759.5 (233.2–1388.1)
GRO-a (pg/mL) 843.1 (368.5–1670.6)
G-CSF (pg/mL) 63.8 (36.2–137.2)
TRAIL (pg/mL) 106.5 (55.7–178.4)
The data are expressed as medians, with the interquartile range in pThe CXC chemokines IL-8 and GRO-a not only have a role
in neutrophil chemotaxis, but also inhibit neutrophil
apoptosis.5,7,8 In addition, pleomorphic cytokine G-CSF has
specific effects on the proliferation, differentiation, and
activation of the neutrophil granulocyte lineage.22 It was
reported that levels of IL-8, G-CSF, and GRO-a were
correlated with the neutrophil count in BAL fluid from ARDS
patients.5,23,24 In our study, the levels of IL-8 and G-CSF, but
not GRO-a, were correlated with the BAL neutrophil count.
In addition, the sFas and TRAIL levels were correlated with
the neutrophil count. It has been suggested that sFas
decreases neutrophil apoptosis in postoperative patients,25
and the Fas/FasL system was shown to induce IL-8
production, which may result in the recruitment of
neutrophils indirectly.26 Membrane-bound TRAIL induces
apoptosis of neutrophils, whilst the soluble form of TRAIL
is not known to have any direct effects on neutrophils.27 The
significant correlations between mediators and the neutro-
phil count do not necessarily imply direct actions of these
mediators on neutrophil recruitment or apoptosis. From a
different perspective, neutrophils are important sources of
sFas28 and TRAIL,29 so some correlations might be mere
secondary phenomena arising from the increased number of
neutrophils.
The Fas/FasL system plays an important role in epithelial
cell apoptosis in ARDS.11,30 Fas antigen, also called APO-1 or
CD95, is a membrane receptor for FasL that belongs to the
tumour necrosis factor (TNF)/nerve growth receptor family.
Fas antigen is expressed on various cells and tissues, including
lung.12 FasL is a transmembrane protein in the TNF family
that induces apoptosis of susceptible cells by cross-linking its
receptor, Fas. Membrane-bound FasL is converted into sFasL
by a matrix metalloproteinase-like enzyme.31 Unlike FasL,
sFas is produced by alternative splicing and inhibits cell
apoptosis by competing with membrane-bound Fas receptors
to bind to FasL.32 Alveolar and airway epithelial cells express
Fas on their surfaces,33 and the alveolar epithelial injuries in
ARDS are caused by enhanced apoptosis due to local activation
of the Fas/FasL system.12
We evaluated the soluble forms of Fas and FasL in BAL
fluid from patients with ARDS. A previous report compared
the concentrations of sFas and sFasL levels in oedema fluids
between ARDS and congestive heart failure, and it was
found that levels of sFas were far higher than those of
sFasL.12 That result was considered unexpected, given that
sFas is essentially anti-apoptotic and sFasL is pro-apoptotic
for alveolar epithelial cells, and the apoptosis of alveolar
epithelial cells in response to soluble mediators such asors and non-survivors in patients with ARDS.
Non-survivors (n ¼ 16) p-Value
213.3 (88.9–1057.6) NS
463.4 (79.0–1373.8) NS
533.6 (435.2–1328.6) NS
183.4 (76.7–315.9) o0.05
68.8 (46.7–181.7) NS
arentheses.
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were comparable or higher than the sFas levels in other
pulmonary diseases.34 In our study, BAL fluid sFas levels were
over 50 times higher than those of sFasL, although the actual
values are not given, since they were too low to be reliable.
Furthermore, the BAL fluid sFasL levels were about 10 times
lower than those of a similar form of ligand, TRAIL. In terms
of concentrations, sFasL may not be sufficient as a single
major contributor in the development of ARDS. One previous
study reported the prognostic significance of intrapulmonary
sFasL levels,11 whilst another did not.12 Although the system
plays a major role in the pathogenesis of ARDS, its soluble
forms only constitute a small portion of the Fas/FasL
system, so they could not account for all of the apoptotic
events in the milieu of injured alveoli.
Apart from significant interrelations amongst various
mediators and their relationship with intra-alveolar neutro-
phils, the clinical implications should be very important for
the utility of the measured mediators from a practical
perspective. From our analysis, G-CSF levels had the most
significant relationship with survival. The other parameters
only differed marginally. BAL fluid G-CSF was also found to
be a significant prognostic factor in one study,5 but not in
another smaller study.22
In this study, IL-8 levels were higher in non-survivors than
in survivors, but did not reach statistical significance.
Likewise, previous reports did not find consistently signifi-
cant differences in the BAL fluid IL-8 levels between
survivors and non-survivors.5,35,36
In analysing the relationships with clinical features, the
sFas levels were correlated with the PaO2/FiO2 ratio,
although not with the final clinical outcome. This implies a
possible protective role of sFas in ARDS. This result is
plausible because sFas binds to and neutralises FasL,
thereby functionally antagonising the Fas/FasL pathway.32
However, Albertine et al.12 reported somewhat contra-
dictory results. They showed that sFas levels in oedema fluid
from ARDS patients were elevated more in patients with
sepsis, shock, or organ failure than in those without,
although no direct correlation with oxygenation status
(PaO2/FiO2) was presented and no significant relationship
with clinical outcome was revealed. Further studies need to
address this discrepancy regarding the clinical implications
of sFas.
The BAL fluid levels of TRAIL were negatively correlated
with the clinical severity scores, suggesting its favourable
role in the systemic inflammatory response and organ
dysfunction. TRAIL, like FasL, belongs to the TNF family
and has structural similarity to FasL.37 TRAIL, which consists
of membrane-bound and soluble forms, has well-known pro-
apoptotic effects on tumour cells.38 However, other func-
tions of TRAIL in benign conditions have been recently
introduced. It was reported that TRAIL promoted the
survival and proliferation of endothelial cells, and down-
regulated the inflammatory chemokines.13,14 These effects
may underlie the negative correlations of TRAIL with clinical
severity scores. However, the role of TRAIL has not yet been
defined in ARDS, and further evaluation is needed to clarify
the significance of TRAIL in ARDS, including measurements
of serum levels.
We acknowledge several limitations of our study. First, as
noted, the small sample size prevented us from furthersubgroup analysis. Second, we did not measure the serum
levels of the parameters. The data might have been more
meaningful if the serum levels had been measured and
compared with the levels in BAL fluid. Third, some bias
occurred in the control group apart from the age difference.
Mechanical ventilation itself causes an inflammatory reac-
tion and the release of mediators, so the differences in
mediator levels are overestimated, and the reliability of the
comparison between patients and controls is thus limited.
In conclusion, we have shown that apoptosis-related
mediators are elevated in BAL fluid from ARDS patients.
Furthermore, they are interrelated with each other and
correlated with the BAL fluid neutrophils. Of the mediators,
G-CSF had prognostic implications, whilst sFas and TRAIL
were related to the clinical parameters. Further studies are
needed to elucidate the detailed pathophysiologic roles and
interplay of the mediators.Conflict of interest
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